Compare LOB & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | RAPT |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | 1025 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2015 | 2019 |
| Metric | LOB | RAPT |
|---|---|---|
| Price | $40.54 | $57.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $42.75 | ★ $56.22 |
| AVG Volume (30 Days) | 402.0K | ★ 6.2M |
| Earning Date | 01-21-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $480,778,000.00 | N/A |
| Revenue This Year | $35.52 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | $18.18 | ★ N/A |
| Revenue Growth | ★ 19.32 | N/A |
| 52 Week Low | $22.68 | $5.67 |
| 52 Week High | $42.89 | $57.86 |
| Indicator | LOB | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 78.75 |
| Support Level | $39.43 | $57.61 |
| Resistance Level | $42.20 | $57.86 |
| Average True Range (ATR) | 1.50 | 0.13 |
| MACD | -0.13 | -0.72 |
| Stochastic Oscillator | 56.52 | 51.72 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.